ASH Agenda for Hematology Research
Updates to ASH’s Research Priorities Coming Soon!
ASH is finalizing its review of the Agenda for Hematology Research to ensure that it continues to reflect the current and emerging research priorities in the field. Thank you to everyone who provided feedback to help keep this important agenda up to date. The deadline to submit comments has now passed, and ASH's updated research priorities will be made available soon.
The ASH Agenda for Hematology Research serves as a roadmap for the prioritization of research support across the hematology community, including recommendations for dedicated resources from funding agencies and foundations that will equip researchers today and in the future to make truly practice-changing discoveries. Learn more.
As genomic profiling is driving significant research progress across the field, it is essential to adopt this technology in drug discovery efforts and build the infrastructure to integrate genomic medicine into the clinic.
Next-generation clinical studies will address important questions about emerging immunologic therapies but require an improved understanding of the basic biology of the immune system, including adaptive immunity, innate immunity, adjuvants, and tumor immune-surveillance.
While genome editing technology represents a highly promising area to advance the future of therapy for hematologic disorders, critical questions must be addressed to effectively translate this approach into clinical use.
New insights and technologies have the potential to optimize the use of stem cells and regenerative medicine, creating “designer” cells that will redefine approaches to the diagnosis and treatment of hematologic diseases.
Research on epigenetics, including its mechanisms and drivers, will elucidate highly valuable targets and lead to potentially transformative treatment regimens for hematologic disorders.
To improve upon the state of care for venous thromboembolic disease (VTE), future research must address unanswered questions about the risk profile of this disease and the accuracy in predicting occurrence and recurrence.
Looking to the future, these areas represent some of the most promising strategies to overcome the limitations of current therapies and accelerate momentum to cure hematologic diseases. Dedicated research funds will enable the pursuit of these compelling opportunities and will equip the next generation of scientists in the field to produce high-impact results and ultimately introduce new standards of care that will not only transform the diagnosis and treatment of patients with hematologic diseases today, but will form the basis for continued scientific progress in hematology and other fields of medicine for years to come.
The Agenda for Hematology Research was developed by the ASH Committee on Scientific Affairs, with input from the Society’s 18 scientific committees and the Executive Committee. ASH thanks all members who contributed to the agenda.
For more information about the ASH Agenda for Hematology Research, contact the ASH Scientific Affairs Manager, Alice Kuaban, MS, at firstname.lastname@example.org.
back to top